ProQR Therapeutics (PRQR) Long-Term Deferred Tax (2022 - 2025)

ProQR Therapeutics (PRQR) has reported Long-Term Deferred Tax for 4 consecutive years, with $3.3 million the latest figure, recorded in Q4 2025.

• Quarterly Long-Term Deferred Tax fell 12.21% year-over-year to $3.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (down 12.21% YoY) and the FY2025 annual result came in at $3.3 million, down 12.21% from the prior year.
• Long-Term Deferred Tax declined to $3.3 million in Q4 2025 per PRQR's latest filing, from $3.7 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for PRQR reached as high as $4.5 million in Q4 2023 and fell as low as $3.3 million in Q4 2025.
• A 4-year average of $4.0 million and a median of $4.1 million in 2022 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax rose 1.58% — and 2024, when it fell 18.17%.
• Year by year, Long-Term Deferred Tax stood at $4.5 million in 2022, then grew by 1.58% to $4.5 million in 2023, then slipped by 18.17% to $3.7 million in 2024, then decreased by 12.21% to $3.3 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $3.3 million, $3.7 million, and $4.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.